Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Total Current Liabilities (2016 - 2025)

Cytokinetics (CYTK) has disclosed Total Current Liabilities for 16 consecutive years, with $202.5 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities changed N/A to $202.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $202.5 million through Dec 2025, changed N/A year-over-year, with the annual reading at $202.5 million for FY2025, N/A changed from the prior year.
  • Total Current Liabilities for Q4 2025 was $202.5 million at Cytokinetics, up from $142.1 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $202.5 million in Q4 2025, with the low at $35.9 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $94.9 million, with a median of $80.9 million recorded in 2021.
  • The sharpest move saw Total Current Liabilities soared 193.29% in 2021, then dropped 5.41% in 2022.
  • Over 5 years, Total Current Liabilities stood at $71.9 million in 2021, then increased by 17.75% to $84.6 million in 2022, then grew by 21.34% to $102.7 million in 2023, then grew by 6.95% to $109.8 million in 2024, then soared by 84.36% to $202.5 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $202.5 million, $142.1 million, and $131.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.